Paradigm Health to acquire Flatiron’s clinical research business
It's an acquisition that aims at forming one of the US's largest oncology trial networks
It's an acquisition that aims at forming one of the US's largest oncology trial networks
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
MRI is particularly valuable in pediatric care due to its non-invasive nature
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
The company is excluding data from the affected sites to maintain the study's integrity
The acquisitions merge DatCard and Sorna’s expertise in clinical data sharing with Avandra’s de-identified patient data aggregation platform
Subscribe To Our Newsletter & Stay Updated